AbbVie Reports P-III Study (INSPIRE) Results of Skyrizi (risankizumab) in P-III Induction Study (INSPIRE) for Ulcerative Colitis
- The P-III study (INSPIRE) evaluating risankizumab (1200mg, IV, q4w) as induction therapy vs PBO in 1554 patients with moderately to severely active UC
- The trial met its 1EPs & 2EPs i.e., patients treated with risankizumab (IL-23 inhibitor) achieved clinical remission (20.3% vs 6.2%); clinical response (64.3% vs 35.7%); endoscopic improvement (36.5% vs 12.1%) & histologic-endoscopic mucosal improvement (24.5% vs 7.7%). The safety profile was consistent with the prior studies across other indications with no new safety risks
- Serious AEs (2.3% vs 10.2%); rates of serious inf. (0.6% vs 1.2%), no adjudicated MACE with no adjudicated anaphylactic reaction events & no malignancy events were reported in the risankizumab group
Ref: AbbVie | Image: AbbVie
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.